Nephrotic Syndrome Clinical Trial
Official title:
Assessment of Coagulation Disorders and of Enoxaparin's Anti-Xa Activity, When Used for Thromboprophylaxis, in Severe Nephrotic Syndrome.
The primary objective is to test the hypothesis that enoxaparin efficacy is reduced in severe nephrotic syndrome. Another purpose is to compare two dosing regimens.
Nephrotic syndrome (NS) is a rare clinical condition characterized by proteinuria exceeding >3.5 g/24h, hypoalbuminemia, dyslipidemia and edema and is associated with hypercoagulable state. In severe cases, with serum albumin ≤2.5 g/dL, the risk of venous thromboembolic events (VTE) is particularly high, and pharmacological prophylaxis is recommended. However, there is a limited evidence of its efficacy and optimal dosing. The study is designed as 3 arms clinical trial, with 2 study groups and a single control group. The study groups will include patients with severe NS parallelly, alternately assigned (1:1) into two enoxaparin dosing regimens. The control group will consisted of individuals without proteinuria and edema, similar in terms of age, anthropometric features and renal function to NS patients, who will be administered a standard enoxaparin dose. A peak anti-Xa activity at the steady state will be measured to determine the plasma concentration of enoxaparin. Additional laboratory tests for markers of NS severity, renal function and coagulation system proteins will be performed. The overhydration and body water compartments will be assessed using bioimpedance spectroscopy technique. Nephrotic patients will be followed up by 12 months to assess overt VTE and adverse events associated with enoxaparin use. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02238418 -
Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria.
|
Phase 4 | |
| Completed |
NCT01895894 -
Mycophenolate Mofetil in Pediatric Steroid Dependent Nephrotic Syndrome
|
Phase 4 | |
| Completed |
NCT01411982 -
Role of PACAP in Nehprotic Syndrome
|
N/A | |
| Recruiting |
NCT00308321 -
Long Term Tapering or Standard Steroids for Nephrotic Syndrome
|
Phase 4 | |
| Active, not recruiting |
NCT03326037 -
Study of The Association of Mutations in The NPHS2 Gene and Nephrotic Syndrome in Children and Adults in Middle East
|
||
| Recruiting |
NCT01240564 -
The Nephrotic Syndrome Study Network (NEPTUNE)
|
N/A | |
| Completed |
NCT01252901 -
Registry for Patients With Wilms' Tumor Suppressor Gene 1 (WT1) Mutation Associated Diseases
|
N/A | |
| Completed |
NCT01197040 -
Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome
|
Phase 3 | |
| Terminated |
NCT00883636 -
Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis
|
N/A | |
| Completed |
NCT00035334 -
Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
|
Phase 2/Phase 3 | |
| Terminated |
NCT00004466 -
Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome
|
Phase 2 | |
| Completed |
NCT02257697 -
A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome
|
Phase 3 | |
| Completed |
NCT00362531 -
Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome
|
Phase 2/Phase 3 | |
| Completed |
NCT00289328 -
Glucocorticoid-induced Osteopenia in Children
|
N/A | |
| Recruiting |
NCT04759274 -
Diuretic Tuner Clinical Decision Support
|
N/A | |
| Completed |
NCT00001212 -
Drug Therapy in Lupus Nephropathy
|
Phase 2 | |
| Recruiting |
NCT05623033 -
The Predictive Value of Dynamic Changes of CD4+T Lymphocytes in Primary Nephrotic Syndrome With Infection
|
||
| Completed |
NCT03332420 -
The Efficacy of Huaiqihuang Granule in Children With Primary Nephrotic Syndrome
|
||
| Not yet recruiting |
NCT05904197 -
Effectiveness of Educational Gamified Cards About Nephrotic Syndrome
|
N/A | |
| Completed |
NCT02438982 -
Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome
|
Phase 3 |